Literature DB >> 10888300

The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors.

T Minko1, P Kopeckova, V Pozharov, K D Jensen, J Kopecek.   

Abstract

PURPOSE: To study the influence of cytotoxicity of macromolecules, VEGF gene expression, and vascular permeability on the enhanced permeability and retention (EPR) effect.
METHODS: Mice bearing xenografts of A2780 multidrug resistant human ovarian carcinoma were treated by free doxorubicin (DOX) and N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound DOX (P(GFLG)-DOX), Texas Red (P-TR), and FITC (P-FITC). Antitumor activity, drug distribution in tumor, vascular permeability, VEGF gene expression, and DNA fragmentation were studied.
RESULTS: The accumulation of free DOX led to the VEGF gene overexpression and increased the vascular permeability, which in turn enhanced the drug accumulation in the same location. This positive feedback loop led to a highly inhomogeneous distribution of the drug within the tumor. In contrast, P(GFLG)-DOX down-regulated the VEGF gene and decreased vascular permeability. This negative feedback seemed to prevent additional drug accumulation in dead necrotic tissue, resulting in a more uniform drug distribution and enhanced the antitumor activity P(GFLG)-DOX.
CONCLUSIONS: The EPR effect significantly differed for macromolecules containing DOX when compared to macromolecules without drug. The cytotoxicity of P(GFLG)-DOX amplified the EPR effect, led to a more homogenous distribution of the drug, increased the average drug concentration in tumor and augmented its efficacy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10888300     DOI: 10.1023/a:1007500412442

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  25 in total

1.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.

Authors:  N Ferrara; W J Henzel
Journal:  Biochem Biophys Res Commun       Date:  1989-06-15       Impact factor: 3.575

2.  Doxorubicin gradients in human breast cancer.

Authors:  J Lankelma; H Dekker; F R Luque; S Luykx; K Hoekman; P van der Valk; P J van Diest; H M Pinedo
Journal:  Clin Cancer Res       Date:  1999-07       Impact factor: 12.531

3.  Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors.

Authors:  B Berse; L F Brown; L Van de Water; H F Dvorak; D R Senger
Journal:  Mol Biol Cell       Date:  1992-02       Impact factor: 4.138

4.  Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary.

Authors:  N Ravindranath; L Little-Ihrig; H S Phillips; N Ferrara; A J Zeleznik
Journal:  Endocrinology       Date:  1992-07       Impact factor: 4.736

5.  Biodistribution of free and N-(2-hydroxypropyl)methacrylamide copolymer-bound mesochlorin e(6) and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts.

Authors:  J J Shiah; Y Sun; C M Peterson; J Kopecek
Journal:  J Control Release       Date:  1999-08-27       Impact factor: 9.776

6.  HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line.

Authors:  T Minko; P Kopecková; V Pozharov; J Kopecek
Journal:  J Control Release       Date:  1998-07-31       Impact factor: 9.776

7.  Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization.

Authors:  S Mesiano; N Ferrara; R B Jaffe
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

8.  A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines.

Authors:  D R Senger; C A Perruzzi; J Feder; H F Dvorak
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

9.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.

Authors:  L E Benjamin; D Golijanin; A Itin; D Pode; E Keshet
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

10.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Authors:  Y Matsumura; H Maeda
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

View more
  11 in total

Review 1.  Conscripts of the infinite armada: systemic cancer therapy using nanomaterials.

Authors:  David A Scheinberg; Carlos H Villa; Freddy E Escorcia; Michael R McDevitt
Journal:  Nat Rev Clin Oncol       Date:  2010-03-30       Impact factor: 66.675

Review 2.  Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.

Authors:  Sharad Mangal; Wei Gao; Tonglei Li; Qi Tony Zhou
Journal:  Acta Pharmacol Sin       Date:  2017-05-01       Impact factor: 6.150

3.  Multifunctional tumor-targeted polymer-peptide-drug delivery system for treatment of primary and metastatic cancers.

Authors:  Pooja Chandna; Jayant J Khandare; Elizabeth Ber; Lorna Rodriguez-Rodriguez; Tamara Minko
Journal:  Pharm Res       Date:  2010-08-11       Impact factor: 4.200

4.  Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide.

Authors:  S S Dharap; Y Wang; P Chandna; J J Khandare; B Qiu; S Gunaseelan; P J Sinko; S Stein; A Farmanfarmaian; T Minko
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-25       Impact factor: 11.205

5.  Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model.

Authors:  Huan Meng; Min Xue; Tian Xia; Zhaoxia Ji; Derrick Y Tarn; Jeffrey I Zink; Andre E Nel
Journal:  ACS Nano       Date:  2011-04-27       Impact factor: 15.881

Review 6.  Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.

Authors:  Darren Lars Stirland; Joseph W Nichols; Seiji Miura; You Han Bae
Journal:  J Control Release       Date:  2013-10-02       Impact factor: 9.776

7.  Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.

Authors:  Huan Meng; Wilson X Mai; Haiyuan Zhang; Min Xue; Tian Xia; Sijie Lin; Xiang Wang; Yang Zhao; Zhaoxia Ji; Jeffrey I Zink; Andre E Nel
Journal:  ACS Nano       Date:  2013-01-04       Impact factor: 15.881

8.  Targeted sialic acid-doxorubicin prodrugs for intracellular delivery and cancer treatment.

Authors:  Sreeja Jayant; Jayant J Khandare; Yang Wang; Ajay P Singh; Nicholi Vorsa; Tamara Minko
Journal:  Pharm Res       Date:  2007-08-01       Impact factor: 4.200

9.  Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models.

Authors:  Yoshinori Kato; Baasil Okollie; Venu Raman; Farhad Vesuna; Ming Zhao; Sharyn D Baker; Zaver M Bhujwalla; Dmitri Artemov
Journal:  Cancer Biol Ther       Date:  2007-03-05       Impact factor: 4.742

10.  VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors.

Authors:  F Röhrig; S Vorlová; H Hoffmann; M Wartenberg; F E Escorcia; S Keller; M Tenspolde; I Weigand; S Gätzner; K Manova; O Penack; D A Scheinberg; A Rosenwald; S Ergün; Z Granot; E Henke
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.